World Journal of Urology

, Volume 30, Issue 2, pp 157–165

Diet and prostate cancer prevention

Topic Paper



To evaluate the present human-based evidence that diet is related to the risk and outcome of prostate cancer.


Review of major case–control and cohort studies, and experimental trials evaluating the effect of diet or dietary constituents on the risk of prostate cancer.


Although non-experimental studies have suggested several dimensions of diet and several dietary components as related to risk and outcome of prostate cancer, the results of these studies are inconsistent. There is limited evidence that a diet that emphasizes plant products is associated with diminished risk of prostate cancer and of aggressive prostate cancer.


The non-experimental epidemiologic evidence that has now accrued justifies trials of dietary intervention for those at elevated risk of prostate cancer.


Diet Nutrition Epidemiology Chemoprevention Prevention 


  1. 1.
    Globocan (2008) Prostate cancer incidence and mortality worldwide in 2008 summary. Accessed 09/2011
  2. 2.
    World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. American Institute for Cancer Research, Washington, DCGoogle Scholar
  3. 3.
    Sonn GA, Aronson WJ, Litwin MS (2005) Impact of diet on prostate cancer: a review. Prostate Cancer and Prostatic Dis 8:304–310CrossRefGoogle Scholar
  4. 4.
    Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H (1977) Latent carcinoma of prostate at autopsy in seven areas collaborative study organized by the international agency for research on cancer, Lyons, France. Int J Cancer 20:680–688PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRefGoogle Scholar
  6. 6.
    Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1995) Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87:1767–1776PubMedCrossRefGoogle Scholar
  7. 7.
    Schuurman AG, Goldbohm RA, Brants HA, Van Den Brandt PA (2002) A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 13:573–582PubMedCrossRefGoogle Scholar
  8. 8.
    Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571–1579PubMedCrossRefGoogle Scholar
  9. 9.
    Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, Schoenberg JB, Silverman DT, Brown LM, Pottern LM, Liff J, Schwartz AG et al (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomark Prevent 8:25–34Google Scholar
  10. 10.
    Giovannucci E, Liu Y, Stampfer MJ, Willett WC (2006) A Prospective Study of Calcium Intake and Incident and Fatal Prostate Cancer. Cancer Epidemiol Biomark Prevent 15:203–210CrossRefGoogle Scholar
  11. 11.
    Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with a-tocopherol and B-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446PubMedCrossRefGoogle Scholar
  12. 12.
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers The selenium and vitamin E cancer prevention trial (SELECT). J Am Med Assoc 301:E1–E13Google Scholar
  13. 13.
    Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH (2011) Vitamin E and the risk of prostate cancer The selenium and vitamin E cancer prevention trial (SELECT). J Am Med Assoc 306:1549–1556CrossRefGoogle Scholar
  14. 14.
    Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, For the Reduce Study Group (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202PubMedCrossRefGoogle Scholar
  15. 15.
    Willett W (1998) Nutritional epidemiology. Oxford University Press, OxfordCrossRefGoogle Scholar
  16. 16.
    Marshall JR, Chen Z (1999) Diet and health risk: risk patterns and disease-specific associations. Am J Clin Nutr 69:1351S–1356SPubMedGoogle Scholar
  17. 17.
    Graham S (1980) Diet and Cancer. Am J Epidemiol 112:247–252PubMedGoogle Scholar
  18. 18.
    Graham S (1986) Epidemiolgic studies of diet and cancer (42420). Proc Soc Exp Biol Med 183:281–286PubMedGoogle Scholar
  19. 19.
    Kolonel LN, Hinds MW, Nomura AMY, Hankin JH, Lee J (1985) Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder, and prostate in Hawaii. Monogr Natl Cancer Inst 69:137–142Google Scholar
  20. 20.
    Andersson SO, Wolk A, Bergstrom R, Giovannucci E, Lindgren C, Baron J, Adami HO (1996) Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 68:716–722PubMedCrossRefGoogle Scholar
  21. 21.
    Gann PH, Ma J, Giovannucci E, Willet WC, Sacks FM, Hennekens CH, Stampfer MJ (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59:1225–1230PubMedGoogle Scholar
  22. 22.
    Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ (2003) Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 157:335–344PubMedCrossRefGoogle Scholar
  23. 23.
    Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, Howe GR, Dreon DM, West DW, Paffenbarger RS (2000) Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomark Prevent 9:795–804Google Scholar
  24. 24.
    Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, Mettlin C, Pontes JE (1983) Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70:687–692PubMedGoogle Scholar
  25. 25.
    Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci E, Stampfer MJ (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86:281–286PubMedCrossRefGoogle Scholar
  26. 26.
    Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willet WC, Giovannucci E (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomark Prevent 12:64–67Google Scholar
  27. 27.
    Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95PubMedCrossRefGoogle Scholar
  28. 28.
    Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park HK, Sanders BB, Smith CL, Taylor JR, For the Nutritional Prevention of Cancer Study Group (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial. J Am Med Assoc 276:1957–1963CrossRefGoogle Scholar
  29. 29.
    Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omen GS, The Carotene Retional Efficacy Trial (CARET) Co-Investigators (2001) Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomark Prevent 10:1069–1076Google Scholar
  30. 30.
    Vogt TM, Ziegler RG, Graubard BI, Swanson CA, Greenberg RS, Schoenberg JB, Swanson GM, Hayes RB, Mayne ST (2003) Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103:664–670PubMedCrossRefGoogle Scholar
  31. 31.
    Allen NE, Morris JS, Ngwenyama RA, Key TJ (2004) A case-control study of selenium in nails and prostate cancer risk in British men. Br J Cancer 90:1392–1396PubMedCrossRefGoogle Scholar
  32. 32.
    Allen NE, Appleby PN, Roddam AW, Tjonneland A, Johnsen NF, Overvad K, Boeing H, Weikert S, Kaaks R, Linseisen J, Trichopoulou A, Misirli G, Trichopoulos D, Sacerdote C, Grioni S, Palli D, Tumino R, Bueno-de-Mesquita HB, Kiemeney LA, Barricarte A, Larranaga N, Sanchez MJ, Agudo A, Tormo MJ, Rodriguez L, Stattin P, Hallmans G, Bingham S, Khaw KT, Slimani N, Rinaldi S, Boffetta P, Riboli E, Key TJ (2008) Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into cancer and nutrition (EPIC)1–3. Am J Clin Nutr 88:1567–1575PubMedCrossRefGoogle Scholar
  33. 33.
    Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW (2000) Association between a-tocopherol, y-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018–2023PubMedCrossRefGoogle Scholar
  34. 34.
    Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int 91:608–612PubMedCrossRefGoogle Scholar
  35. 35.
    Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM (2011) Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevent Res. doi:10.1158/1940-6207.CAPR-10-0343
  36. 36.
    Kristal AR, Stanford JL (2004) Cruciferous vegetables and prostate cancer risk: confounding by PSA screening. Cancer Epidemiol Biomark Prevent 13:1265Google Scholar
  37. 37.
    Chan JM, Gann PH, Giovannucci EL (2005) Role of diet in prostate cancer development and progression. J Clin Oncol 23:8152–8160PubMedCrossRefGoogle Scholar
  38. 38.
    Zhang Y, Munday R, Jobson HE, Munday CM, Lister C, Wilson P et al (2006) Induction of GST and NQO1 in cultured bladder cells and in the urinary bladder of rats by an extract of broccoli (Brassica Italica) sprouts. J Agric Food Chem 54:9370–9376PubMedCrossRefGoogle Scholar
  39. 39.
    Brooks JD, Paton VG, Vidanes G (2001) Potent induction of phase II enzymes in human prostate cells by sulforaphane. CEBP 10:949–954Google Scholar
  40. 40.
    Kristal AR, Cohen JH, Qu P, Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomark Prevent 11:719–725Google Scholar
  41. 41.
    Schuurman AG, Goldbohm RA, Dorant E, Van Den Brandt PA (1998) Vegetable and fruit consumption and prostate cancer risk: a cohort study in the Netherlands. Cancer Epidemiol Biomark Prevent 7:673–680Google Scholar
  42. 42.
    Gronberg H, Damber L, Damber JE (1996) Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 155:969–974PubMedCrossRefGoogle Scholar
  43. 43.
    Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97PubMedCrossRefGoogle Scholar
  44. 44.
    Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR (2006) Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomark Prevent 15:1977–1983CrossRefGoogle Scholar
  45. 45.
    Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR (2005) Obesity and prostate cancer clinical risk factors at presentation: data from CaPsure. J Urol 173:732–736PubMedCrossRefGoogle Scholar
  46. 46.
    Hsing AW, Sakoda LC, Chua SC (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(supplement):843S–857SGoogle Scholar
  47. 47.
    Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS (2006) Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-1, insulin-like growth factor binding protein-3, and insulin-like growth factor-1 receptor. Cancer Epidemiol Biomark Prevent 15:2461–2466CrossRefGoogle Scholar
  48. 48.
    Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Gronbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quiros JR, Ardanaz E, Navarro C, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R (2007) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prevent 16:1121–1127CrossRefGoogle Scholar
  49. 49.
    Fair WR, Wynder EL (1996) Editorial: prostate cancer—nutrition adjunct therapy. J Urol 156:1364–1365PubMedCrossRefGoogle Scholar
  50. 50.
    Klotz L (2005) Active surveillance for prostate cancer: for whom? JCO 23:8165–8169CrossRefGoogle Scholar
  51. 51.
    Klotz L, Zhang L, Adam L, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRefGoogle Scholar
  52. 52.
    Khan MA, Carter HB, Epstein JI et al (2003) Cancer prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170:2274–2278PubMedCrossRefGoogle Scholar
  53. 53.
    Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB (2006) Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98:355–357PubMedCrossRefGoogle Scholar
  54. 54.
    Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2365PubMedCrossRefGoogle Scholar
  55. 55.
    Parsons JK, Newman V, Mohler JL, Pierce JP, Paskett E, Marshall J (2008) The men’s eating and living (MEAL) study: a cancer and leukemia group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology 72:633–637PubMedCrossRefGoogle Scholar
  56. 56.
    Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Marshall J (2008) Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study. British J Urol Int 101:1227–1231CrossRefGoogle Scholar
  57. 57.
    Parsons JK, Newman V, Mohler J, Pierce JP, Flatt SW, Messner K, Marshall JR (2009) Dietary intervention after definitive therapy are localized prostate cancer: results from a pilot study. Can J Urol 16:4648–4654PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Roswell Park Cancer InstituteBuffaloUSA

Personalised recommendations